title: Amitifadine, a triple monoamine uptake inhibitor, reduces binge  drinking and negative affect in an animal model of co-occurring  alcoholism and depression symptomatology.
abstract: The co-occurrence of alcoholism and depression is highly prevalent and difficult to treat. In an animal model of binge drinking that exhibits abstinence-induced behaviors reminiscent of negative affective states, the triple monoamine uptake inhibitor, amitifadine, produced a selective, dose dependent attenuation of binge drinking. Amitifadine also reversed abstinence-induced increases in the intracranial self-stimulation threshold, a model of anhedonia, and immobility in the forced swim test, reflecting behavioral despair. In view of the safety profile of amitifadine in humans, including low risk for weight gain, lack of sexual side effects, and low potential for abuse, we hypothesize that amitifadine will be effective in treating co-occurring alcoholism and depression.
authors.affiliation: Neuropsychopharmacology Laboratory, Department of Psychiatry and Behavioral Sciences, Howard University College of Medicine, Washington, DC 20060, USA.
authors.forename: Kaitlin T
authors.initials: KT
authors.lastname: Warnock
authors.forename: Andrew R S T
authors.initials: AR
authors.lastname: Yang
authors.forename: Heon S
authors.initials: HS
authors.lastname: Yi
authors.forename: Harry L
authors.initials: HL
authors.lastname: June
authors.forename: Timothy
authors.initials: T
authors.lastname: Kelly
authors.forename: Anthony S
authors.initials: AS
authors.lastname: Basile
authors.forename: Phil
authors.initials: P
authors.lastname: Skolnick
authors.forename: Harry L
authors.initials: HL
authors.lastname: June
mesh_terms: D000339:Affect / Q000187:drug effects*; D000437:Alcoholism / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology; D000818:Animals; D001372:Aza Compounds / Q000494:pharmacology*; D063425:Binge Drinking / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D015306:Biogenic Monoamines / Q000378:metabolism; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D003863:Depression / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology; D004195:Disease Models, Animal; D000431:Ethanol / Q000097:blood; D006801:Humans; D007099:Imipramine / Q000494:pharmacology; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D051381:Rats
chemical_list: C474071:1-(3,4-dichlorophenyl)-3-azabicyclo-(3.1.0)hexane hydrochloride; D001372:Aza Compounds; D015306:Biogenic Monoamines; D019086:Bridged Bicyclo Compounds, Heterocyclic; D000431:Ethanol; D007099:Imipramine